

January 20, 2012

*CURRICULUM VITAE*

**ANIRBAN BASU**

Department of Health Services, School of Public Health, University of Washington  
1959 NE Pacific St, Magnuson Health Sciences Center, Room H-694, Box 357660, Seattle, WA, 98195-7660  
Email: basua@uw.edu Tel: (206) 616-2986 Fax: (206) 543-3964  
Web: <http://faculty.washington.edu/basua>

**CITIZENSHIP:** USA

**EDUCATION**

B.S., Pharmaceutical Technology, Jadavpur University, India, (1995).  
M.S., Pharmaceutical Sciences, University of Toledo, (1997).  
M.S., Biostatistics, University of North Carolina, Chapel Hill (1999).  
Ph.D., Public Policy (Health Economics), University of Chicago, (2004).  
Dissertation: *Three essays in medical cost-effectiveness analysis.*

**PROFESSIONAL EXPERIENCE**

RESEARCH ASSOCIATE (Intern), Statistics Collaborative Inc., Washington DC (1997).  
RESEARCH ASSISTANT (Student), Collaborative Studies Coordinating Center, UNC-CH (1997-1999).  
CONSULTANT (Intern), Dept. of Statistics, Abbott Laboratories Inc., Abbott Park, IL (1999).  
RESEARCH ASSISTANT (Student), National Opinion Research Center, University of Chicago, IL (2000).  
INSTRUCTOR, Section of General Internal Medicine, Department of Medicine, University of Chicago, IL (2004-2006).  
PROJECT ANALYST, Decision and Information Sciences, Argonne National Laboratory, IL (2004-2006).  
MEMBER, Clinical Cancer Genetics and Prevention Program at the University of Chicago Cancer Center, Chicago, IL (2006-2010).  
ASSISTANT PROFESSOR, Department of Medicine, University of Chicago, IL.  
    Section of General Internal Medicine (2006 - 2008).  
    Section of Hospital Medicine (2008 - 2010)  
AFFILIATE, Center for Health and the Social Sciences, University of Chicago, Chicago, IL (2005- ).  
EXTERNAL AFFILIATE, Health Econometrics and Data Group, The University of York, UK (2007- ).  
FACULTY RESEARCH FELLOW, National Bureau of Economic Research, Cambridge, MA (2008- ).  
EXTERNAL AFFILIATE, Center for Health and the Social Sciences, University of Chicago, Chicago, IL (2011-).  
AFFILIATE INVESTIGATOR, Cancer Prevention Program, Fred Hutchinson Cancer Research Center, WA, (2011-)  
ASSOCIATE PROFESSOR, University of Washington, Seattle (2011 - )  
    Department of Health Services, School of Public Health  
    (ADJUNCT) Department of Pharmacy, School of Pharmacy

**AWARDS & HONORS**

Diploma in Computer Programming and Applications from National Computing Center, UK with DISTINCTION award (1993).  
First Class Honors in Bachelors Degree in Pharmaceutical Sciences (1995).  
Outstanding Academic Performance, Rho Chi Society, University of Toledo, OH (1996).  
Irving Harris Fellowship Award from the School of Public Policy, University of Chicago (1999-2004).  
Winner of Student Paper competition, Health Policy Statistics Section for the 2003 Joint Statistical Meetings (2003).

Winner of Student Travel Award, International Conference Health Policy Research (2003).  
Wodecroft Young Investigator Award, National Alliance for Research of Schizophrenia and Depression (NARSAD) (2005).  
Research Excellence Award for Methodological Excellence, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (2007).  
Alan Williams Health Economics Fellowship, University of York, UK (2008).  
ISPOR Bernie O'Brien New Investigator Award, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (2009).  
2009 Labelle Lecturer in Health Services Research, McMaster University, Canada (2009).  
Society for Medical Decision Making Comparative Effectiveness Research Essay Contest Winner (2009).

## TEACHING EXPERIENCE

TEACHING ASSISTANT, College of Pharmacy, University of Toledo, Toledo, OH (1995-1997).  
TEACHING ASSISTANT, Department of Biostatistics, University of North Carolina at Chapel Hill, NC (1998).  
TEACHING ASSISTANT, Harris School of Public Policy Studies, University of Chicago, IL (2000-2003).  
GRADUATE ASSISTANT, University of Chicago, IL (2000-2004).  
STATISTICAL CONSULTANT AND MENTOR to many faculties, research scholars and medical students in the Department of Medicine (4 hours/week) (2004- )  
INVITED LECTURER, Global Health Economics, Amgen Inc., Thousand Oaks, CA (2009)  
*Methods to adjust for hidden bias in observational research using instrumental variables* (1-day course)  
INVITED LECTURER, Department of Economics, National University of Ireland, Galway (2010)  
*Medical Decision Analysis and Cost-effectiveness Analysis* (5-day course to Masters and PhD students)  
ANNUAL MEETING FACULTY, Society for Hospital Medicine Annual Meeting (2010)  
*Comparative Effectiveness and Cost-effectiveness Research* (90-minute session, with David Meltzer)  
LECTURER, University of Chicago, IL (2007- 2011)  
*Advanced Applications of Cost-Effectiveness Analysis in Health* (Public Policy 44800), Spring 2007 (with David Meltzer).  
Teach five 3 hour sessions.  
*Applied Medical Cost-Effectiveness Analysis* (Public Policy 46000) Winter 2008-2010 (with William Dale, Elbert Huang, David Meltzer & Harold Pollack). Teach two 3 hour sessions.  
*Advanced Methods for Comparative Effectiveness Research (Public Policy 44800)* Spring 2010 & 2011 (with David Meltzer). Teach eight 3 hour sessions.  
INVITED LECTURER, U.S. Food and Drug Administration, Silver Spring, MD (2011)  
*Comparative effectiveness research: Introduction and Methods* (1-day course)

## ADVISING

### THESIS CHAIR OR COMMITTEE MEMBER

Committee Member, Jennifer Humensky (PhD, 2003-2009, University of Chicago). (Presently: Research Director, NYS Center of Excellence for Cultural Competence, New York State Psychiatric Institute)  
Committee Member, Anjali Oza (PhD, 2009-2010, University of Chicago) (Presently: Associate, Analysis Group)  
Thesis Chair, Vasanthi S. Gowri, MD (MPh, 2011, University of Washington) (Presently: Hospitalist, Swedish Medical Center, Edmunds WA)

### MENTOR

Lisa Shah M.D. (2006-2010, University of Chicago). (Presently: Senior Manager, Avalere Health, Bethesda, MD)  
Jing Guo, Doctoral Student (2009 - 2010, University of Chicago)

### ADVISORY BOARD

Member for Amgen Inc. on Alternative Estimators for Unbiased Treatment Effects (2008)

Member for Ortho-McNeil Janssen Scientific Affairs LLC. for People with Mental Illness in the Criminal Justice System (2009)

#### Student Research Assistants:

Emily Kuo @ University of Chicago, 2005-2006, Currently at Institute of Medicine, Washington University at St. Louis.

Aaron Winn @ University of Chicago, 2006 - 2007. Currently at Ideas42.org

Olena Verbenko @ University of Chicago, 2007-2008. Currently, PhD Candidate, Harris School University of Chicago.

Yihe (Nina) Gao @ University of Chicago, 2010 - 2011. Currently, MD-PhD Student, University of Chicago.

Joelle Abramowitz @ University of Washington, 2011 - Present. Currently, PhD Student, Dept. of Economics, UW.

Maria Agapova @ University of Washington, 2011. Currently, PhD Student, PORPP, UW.

#### **EDITORIAL ACTIVITIES**

ASSOCIATE EDITOR, Health Economics (*Handle up to 15 papers a year*) (2009- )

ASSOCIATE EDITOR, Journal of Health Economics (*Handle up to 5 papers a year*) (2008- )

SECTION CO-EDITOR. *Health Econometrics*, Encyclopedia of Health Economics (ed. Tony Cuyler, Elsevier) (2010 -)

SECTION CO-EDITOR. *Economic Evaluation*, Encyclopedia of Health Economics (ed. Tony Cuyler, Elsevier) (2010 -)

REVIEWER (2003- ) for

***Applied Economics***. Journal of Health Economics, Health Economics, Journal of Mental Health Policy and Economics, PharmacoEconomics

***Statistics***. Statistics in Medicine, Journal of the Royal Statistical Society- Series B, Health Services and Outcomes Research Methodology, Operations Research

***Health Services Research***. Medical Decision Making, Value in Health, Pharmacoepidemiology and Drug Safety, Health Services Research

***Clinical***. Stroke, Journal of Clinical Psychopharmacology, Stroke, Journal of the National Cancer Institute

***Grants***. National Science Foundation, Research Grants Council (RGC) of Hong Kong, National Institute of Health (NIH)

#### **PROFESSIONAL AFFILIATIONS**

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

American Statistical Association (ASA)

International Health Economics Association (iHEA)

American Society of Health Economists (ASHE)

Society for Medical Decision Making (SMDM)

#### **PROFESSIONAL SERVICE**

Health Policy Statistics Section, American Statistical Association (<http://www.amstat-online.org/sections/hpss/info.htm>)

Member, International Conference for Health Policy Research (ICHPR) Scientific Planning Committee, Boston, MA (2005).  
Program Chair-Elect (2007).

Program Chair (2008).

Member, International Conference for Health Policy Statistics (ICHPS), Scientific Planning Committee, Philadelphia, PA (2008).

Conference Co-Chair, International Conference for Health Policy Statistics (ICHPS), Washington DC (2010).

Society for Medical Decision Making (www.smdm.org)

Member, Nominations Committee (2008).

Co-Chair, Scientific Committee for Annual Meeting (2009).

Co-Chair, Scientific Committee for Annual Meeting (2010).

Annual Conference Co-Chair, Chicago IL (2011).

Annual Health Econometrics Workshop (www.healtheconometrics.org)

Founding Member and the Chair of Inaugural Conference, Chicago, IL (2009)

Member, Organizing Committee (2010 & 2011).

Others

Member, American Society of Health Economist (ASHE) Scientific Committee (2005-2007).

Committee Member, Behavioral Health Theme, Annual Research Meeting, Academy Health (2008).

Program Committee Member, The 14th NIMH Biennial Research Conference on the Economics of Mental Health: Toward Building a High Performance Mental Health System (2008).

Member of Technical Panel for Johns Hopkins University Evidence-Based Practice Center Project: *Evaluating Economic Outcomes in Systematic Reviews* (2008-2010).

Committee Member, Comparative Effectiveness Research Theme, Annual Research Meeting, Academy Health (2010 & 2011)

Chair, AHRQ Comparative Effectiveness Research Special Interest Group (2010).

Steering Committee Member. Chicago-Area Decide-2 Network Center. (2010-).

Trustee (Elected), Society for Medical Decision Making (2010- ).

Member, NHLBI Value of Information Working Group (2010).

## CURRENT RESEARCH SUPPORT

Title	Role	Type; Sponsor	Dates	Total
A comprehensive probabilistic micro-simulation model for cost-effectiveness analysis of pharmacological treatment algorithms in schizophrenia	Principal Investigator	1R01 MH083706-01 (NIH-NIMH)	09/01/2008 - 08/30/2013	\$1,970,439 (6.0 FTE)
Advancing Instrumental Variable Methods in Comparative Effectiveness Research	Principal Investigator	1 RC4 CA155809-01 (NCI)	9/28/2010-8/31/2013	\$1,472,354 (2.40 FTE)
Instrumental Variable Methods for Censored Cost Data and an Application in Prostate Cancer	Principal Investigator	R01 (NIH)	7/1/2011-6/30/2014	\$1,613,190 (3.00 FTE)
Monoclonal Antibodies in Cancer Care: Is Underinsurance an Access Barrier	Co-Investigator PI: Shih (U of Chicago)	1 R01 HS18535-01 (AHRQ)	09/01/2009 - 08/31/2013	313,612 (1.80 FTE)

## PENDING RESEARCH SUPPORT

Title	Role	Type; Sponsor	Dates	Total
Comparative Effectiveness of Dynamic Patterns of Glucose Lowering Therapies	Co-Investigator PI: Huang (UofC)	R01; (AHRQ)	12/1/2010-11/30/2015	\$1,626,108 (2.40 FTE)

## PAST RESEARCH SUPPORT

Title	Role	Type; Sponsor	Dates	Total
Self-Selection in Prostate Cancer Treatments	Co-Investigator PI: Meltzer (UofC)	Pfizer Cost-effectiveness Grant	04/01/2007-12/1/2009	\$89,489 (1.20 FTE)
Causal Estimation of the Intention-To-Treat Treatment Effect in Randomized Trials	Principal Investigator	Center for Health Administration Studies (CHAS) Seed Grant	07/01/05 – 06/30/06	\$7,500
Measuring spillover effects of prostate cancer patients' health on their partners	Principal Investigator	UofC, Cancer Research Center, Cancer and Social Sciences Pilot Project	03/01/05 - 6/30/07	\$20,000
Model for cost-effectiveness analysis of the REACH-OUT Chicago Children's Diabetes Prevention Project	Principal Investigator	The Chicago Center of Excellence in Health promotion Economics, Pilot Grant Award	03/01/05 - 02/28/06	\$18,608
Estimating risks and costs of cardiovascular diseases associated with the long-term use of atypical antipsychotics in schizophrenia	Principal Investigator	NARSAD Young Investigator Award	07/01/05 – 06/30/08	\$60,000
Measuring the effects of patient's health on family members' quality of life and incorporating them in cost-effectiveness analysis	Principal Investigator	Pfizer Cost-effectiveness Grant	01/01/06 – 12/31/07	\$60,000
Quality-of-life and willingness-to-pay for clinical symptoms and social outcomes of patients with schizophrenia	Principal Investigator	University of Chicago CCEHPE Pilot Grant	07/01/07 – 06/30/08	\$22,000
REACH-OUT Chicago Children's Diabetes Prevention Project	Co-Investigator PI: Burnet (UofC)	R01, NIDDK(NIH) 1 R18 DK62991-01A2	9/30/04 - 6/30/09	\$2,049,866 (3.75 FTE)
Artificial Pancreas Project Health Economics Follow-On Study	Co-Investigator PI: O'Grady (NORC)	Juvenile Diabetes Research Foundation 22-2006-1126	9/01/06 – 8/31/09	\$459,388 (2.40 FTE)

## INVITED LECTURES AND PROFESSIONAL PRESENTATIONS

### *Topics:*

Personalized Medicine and Economic Evaluations.

Should everyone follow results from large effectiveness trials?

Valuing information in health.

Aligning information with decision-making.

Estimating decision-relevant comparative effects using instrumental variables.

Intensive versus extensive margins in comparative effectiveness research.

Economics and econometrics of individualization in comparative effectiveness research.

Regression estimators for quality of life and quality-adjusted life years.  
Economics of risk stratification.  
Use of decision models in the regulation of medical devices.  
Using instrumental variable analyses to inform policy.  
Modeling healthcare expenditures.  
Estimating lifetime or episode-of-illness costs under censoring.  
Individualizing comparative effectiveness research for diagnostic imaging.  
The impact of comparative effectiveness research on health and health care spending.  
Welfare consequences of comparative effectiveness research.  
Tragedy of averages in comparative effectiveness research: The case for antipsychotics and diabetes.  
Comparative effectiveness research: Another emperor with no clothes?  
Comparative effectiveness research in prostate cancer: building the blocks.  
Antipsychotics and diabetes in schizophrenia: Did comparative effectiveness research make a difference?  
Antipsychotics-induced economic burden of diabetes in schizophrenia.  
Economic incentives to invest in comparative effectiveness research using Bayesian adaptive trials.  
The impact of the Medicare Part D prescription benefit on drug utilization and expenditures: the case for dual-eligibles.  
Use of propensity scores in non-linear response models.  
A time trade-off method to elicit preferences of spouses about the influence of their husbands' potential prostate cancer health states on them.  
Understanding assumptions behind propensity scores versus instrumental variable estimators: how do we interpret estimates of incremental costs?  
Risk prediction index for new onset major depression in the national longitudinal study of adolescent health.  
A simple linear function to predict joint state utilities from single state utilities in prostate cancer.  
Use of instrumental variables in the presence of heterogeneity and self-selection: An application in breast cancer patients.  
Spillover effects of health on family members: Theoretical and measurement issues.  
Risk adjustment with flexible link and variance function models.  
Impact of heart failure on 1-year costs after myocardial infarction related hospitalization: an application using a flexible link and variance function model.  
Comparing alternative models: log vs Cox proportional hazard.  
Estimating marginal and incremental effects on health outcomes using flexible link and variance function parameters.  
Family perspective in economic evaluation of medical technology (Alternative title Friends, families and cost-effectiveness analysis).  
Modeling costs with generalized gamma regressions.  
Hierarchical Linear Models.

***Venues: Intramural***

**University of Chicago, Chicago IL:**

Demography Workshop, October 2002.  
Health Studies Seminar Series, April 2003, January 2008, November 2008.  
Center for Health Administration (CHAS) Workshop, November 2003.  
Health Economics Workshop, June 2001, October 2003, March 2005, June 2006, January 2010.  
Research in Progress, General Internal Medicine, March 2004, March 2006.  
Operations Research and Management, Booth School of Business, October 2010.

**University of Washington, Seattle WA:**

PORPP Graduate Seminar, January 2011, November 2011.

CHASE Work-in-Progress Session, March 2011.

Department of Psychiatry Research Seminar, October 2011.

Institute of Health Metrics and Evaluation (IHME), December 2011.

Center for Statistics and the Social Sciences (CSSS) Seminar Series, February 2012.

***Venues: National***

**2002**

Invited Speaker, American Public Health Association Annual Meeting, Philadelphia, November.

**2003**

International Biometric Society (ENAR) Spring Meeting, Tampa, April.

International Health Economics Association (iHEA) Bi-annual Congress, San Francisco, June.

Tools and Methods for Designing, Performing, and Reporting Primary Care Research Based Practice Networks Research.

Sponsored session by The Agency for Healthcare Research and Quality, Washington DC, July.

Joint Statistical Meeting, Health Policy Statistics Section, San Francisco, August.

Society for Medical Decision Making (SMDM) Annual Meeting, Chicago, October.

International Conference on Health Policy Research, Chicago, October.

**2004**

Department of Health Policy and Administration, Yale University, May.

Keynote Speaker, Third Annual Advanced Research Methods Symposium, Center for Disease Control, May.

Society for Medical Decision Making, Annual Meeting, October.

**2005**

Department of Health Care Policy, Harvard Medical School, January.

Invited Speaker, International Conference on Health Policy Research (iHEA) Bi-annual Meeting, Boston, October.

Center for Pharmacoeconomics Research, University of Illinois at Chicago, Department of Pharmacy Administration, Chicago, August.

**2006**

American Society for Health Economists (ASHE) Inaugural Meeting, Madison WI, June.

Health Economics Brown Bag Seminar Series, Department of Economics, University of Illinois at Chicago, Chicago, September.

Society for Medical Decision Making, Annual Meeting, October.

**2007**

Academy Health, Annual Research Meeting, June.

Society for Medical Decision Making, Annual Meeting, October.

**2008**

Invited Speaker, International Conference for Health Policy Statistics (ICHPS), Philadelphia, January.

Center for Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare, Northwestern University, March.

2nd Biennial Conference of the American Society of Health Economists, Duke NC, June.

Amgen Alternative Estimators for Unbiased Treatment Effects Advisory Board, July.

Invited Speaker, Society for Medical Decision Making, Annual Meeting, October.

Invited Speaker, Society for Judgment and Decision Making, Annual Meeting, November.

## **2009**

Invited Speaker, International Society for Pharmacoeconomics and Outcomes Research, Annual Meeting, May.

20th NIMH Conference on Mental Health Services Research (MHSR), Washington DC, July.

Invited Speaker, Grand Rounds, Department of Psychiatry, Vanderbilt University, June.

Invited Speaker, Specialized Programs of Research Excellence (SPORE) in prostate cancer, Northwestern University, September.

The 31st Annual Meeting of the Society for Medical Decision Making, Hollywood CA, October.

20th Annual Health Economics Conference, Boston MA, October.

Invited Speaker, Rice/University of Houston Empirical Seminar Series, October.

## **2010**

Invited Panelist, RSNA/NIBIB Workshop on Comparative Effectiveness Research (CER) for Diagnostic Imaging, Chicago IL, April.

3rd Biennial Conference of the American Society of Health Economists. Cornell, Ithaca NY, June.

Invited Speaker, Academy Health Annual Research Meeting, Boston, MA, June.

Invited Speaker, Health Economics Resource Center Cyber Seminar, USVA, June.

Invited Panelist, *Responding to the National CER Agenda: Evolving Data Sources and Analytics*, Lewin Center for Comparative Effectiveness Research, Washington DC, June.

Invited Speaker, Department of Health Services Research, School of Public Health, University of Washington, WA, August.

Invited Speaker, Workshop sponsored by FDA/Center for Devices and Radiological Health, August.

Invited Speaker, Pfizer Statistics Group, New York, October.

## **2011**

Invited Speaker, Fourth Annual Bayesian Biostatistics Conference, University of Texas-MD Anderson, Houston, January.

Invited Panelist, 7th Annual Scientific Meeting, The International Society for CNS Clinical Trial and Methodology, Washington DC, February.

Invited Speaker, The Robert Wood Johnson Foundation Physician Faculty Scholars Program (RWJF PFSP), Conference on Comparative Effectiveness Research, Stanford University, CA, February.

Invited Speaker, Institute of Clinical and Translational Sciences CER Seminar, University of Iowa, March.

Invited Plenary Speaker, Western Pharmacoeconomics Conference, University of Washington, April.

Invited Speaker, Academy Health Annual Research Meeting, Seattle, WA, June.

Invited Speaker, Joint Statistical Meetings, Miami, FL, August.

Invited Speaker, Mayo Clinic, Rochester MN, September.

## **2012**

Invited Speaker, AHRQ-SMDM Research Seminar Series, February.

## ***Venues: International***

### **2005**

International Health Economics Association (iHEA) Bi-annual Congress. Organized session on Health Econometrics for Cost and Utilization Data. Barcelona, July.

### **2007**

International Health Economics Association (iHEA) Bi-annual Congress. Copenhagen, July.

## 2008

CHE-TEEHTA Seminar, University of York, York UK, May.

Section of Public Health and Health Policy, University of Glasgow, UK, May.

HEDG Group, University of York, York, UK, May.

17<sup>th</sup> European Workshop of Econometrics and Health Economics, Coimbra, Portugal, September.

## 2009

18<sup>th</sup> European Workshop of Econometrics and Health Economics, Cagliari, Italy, September.

Invited Speaker, 2009 Labelle Lecture, McMaster University, Canada, October.

## 2010

2010 Joint Statistical Meetings, Vancouver, Canada, August.

## 2011

Invited Speaker, The Second International Symposium on Biopharmaceutical Statistics, Berlin, Germany.

International Health Economics Association (iHEA) Bi-annual Congress. Toronto, Canada, July.

20<sup>th</sup> European Workshop of Econometrics and Health Economics, Cagliari, York, UK, September.

## 2012

Invited Delegate, National Seminar on 'Economic and Social impact of Cancer in India', Cancer Foundation of India, January.

Invited Speaker, Personalised Medicine in Canada: A Multi-Stakeholder Workshop to Examine the Canadian Perspective, Ottawa, CA, January.

Invited Speaker, Third Australasian Workshop on Econometrics and Health Economics, Sydney NSW, Australia. April.

### ***Discussant for:***

*Use of Bayesian Net Benefit regression to update cost-effectiveness analysis.* The 13<sup>th</sup> NIMH Biennial Research Conference on the Economics of Mental Health. Washington DC, September 2006.

*Budget constraints in expected utility analysis.* 2nd Biennial Conference of the American Society of Health Economists. Duke NC, June 2008.

*Health utility crosswalks: a Bayesian Beta regression approach.* 3rd Biennial Conference of the American Society of Health Economists. Cornell, Ithaca NY, June 2010

*Using Medicare for Comparative Effectiveness Research.* 3rd Biennial Conference of the American Society of Health Economists. Cornell, Ithaca NY, June 2010

*Accounting for Heterogeneity in Treatment Selection: The Case of Revascularization.* 3rd Biennial Conference of the American Society of Health Economists. Cornell, Ithaca NY, June 2010

*Adverse Selection, Moral Hazard and the Demand for Medigap Insurance.* Nineteenth European Workshop on Econometrics and Health Economics, September 2010.

*Effects of Eating Disorder Parity Laws on Adolescent Health Behaviors.* The 15th Biennial Research Conference on the Economics of Mental Health: Comparative Effectiveness and Mental Health Care Financing, September, 2010

*Empirical Comparative Effectiveness Research: Data, Statistical Analysis, and the Evidence Base of Evidence-based Healthcare.* International Health Economics Association (iHEA) Bi-annual Congress. Toronto, Canada, July, 2011.

*The Role of the Expected Value of Individualized Care in Cost-effectiveness Analysis and Decision Making.* International Health Economics Association (iHEA) Bi-annual Congress. Toronto, Canada, July, 2011.

## PUBLICATIONS (book chapters)

1. Polsky D, **Basu A**. Selection bias in observational data. In *Elgar Companion to Health Economics*. Ed. Jones A., Chap 43: 455 – 465, Edward Elgar Publishing Inc., UK, 2006. (2nd. edition, forthcoming 2011)
2. **Basu A**, Lehman A. Decision Analytic Techniques. In *Difficult Decisions in Thoracic Surgery - An Evidence-Based Approach*. Ed. Ferguson M., Springer, NY, 2007. (2nd. edition, forthcoming 2011)
3. Meltzer D, **Basu A**, and Conti R. The Economics of Comparative Effectiveness Studies: Societal and Private Perspectives. Draft manuscript prepared at the request of the IOM Roundtable on Evidence-Based Medicine, University of Chicago, 2007.
4. Sculpher M, **Basu A**. Heterogeneity in economic evaluations. *Economic Evaluation*, Encyclopedia of Health Economics (ed. Tony Cuyler, Elsevier) (forthcoming 2011)

## PUBLICATIONS (letters, editorials)

1. **Basu A**. Cost-effectiveness of olanzapine as a first-line treatment: A comment. *Value in Health* (Letter) 2006; 9(5): 357. [PMID: 16961554]
2. **Basu A**, Meltzer D. Modeling Comparative Effectiveness and the Value of Research. *Annals of Internal Medicine* (Editorial) 2009; 151: 210-211. [PMID: 19652188]

## BOOK REVIEWS

**Basu A**. Review of *Bayesian Econometric Methods* by Koop, Poirier and Tobias. *Journal of the American Statistical Association* 2009; 104(487): 1273.

## PUBLICATIONS (original peer-reviewed articles)

1. **Basu A**, Tong P, Alexander KS, Dollimore D. Extension of the compartment theory for hindered settling behavior." *S.T.P. Pharma Sciences* 1997; 7(3): 215-222.
2. Tong P, **Basu A**, Alexander KS, Dollimore D. Development of a new theory for hindered settling suspensions. *S.T.P. Pharma Sciences* 1998; 8(4): 241-247.
3. Abdalla I, **Basu A**, Hellman S. An evidence-based analysis of the management of localized prostate cancer. *The Cancer Journal* 2002. Jan-Feb; 8(1): 40-6. [PMID: 11895202]
4. Meltzer D, Chung J, **Basu A**. Does competition under Medicare prospective payment selectively reduce expenditures on high-cost patients? *RAND Journal of Economics* 2003; 33(3): 447-468. [PMID: 12585302]
5. Jani AB, **Basu A**, Heinmann R, Hellman, S. Sentinel node versus axillary node dissection for the early stage breast cancer: A comparison using a utility-adjusted NNT (Number Needed to Treat) analysis. *Cancer* 2003; January; 97(2): 359-366. [PMID: 12518360]
6. Jani AB, **Basu A**, Abdalla I, Connell PP, Krautz L, Vijayakumar S. The impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate or high-risk prostate cancer. *American Journal of Clinical Oncology* 2003; August 26(4):382-385. [PMID: 12902891]
7. **Basu A**, Manning WG, Mullahy J. Comparing alternative models: log vs Cox proportional hazard? *Health Economics* 2004; 13(8): 749-765. [PMID: 15322988]
8. **Basu A**. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. *Schizophrenia Research* 2004; 71(2-3): 445-462. [PMID: 15474916]
9. **Basu A**, Rathouz P. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. *Biostatistics* 2005; 6(1): 93-109. [PMID: 15618530]
10. Manning WG, **Basu A**, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes. 2003 NBER Working Paper No. t0293. *Journal of Health Economics* 2005; 24(3): 465-488. [PMID: 15811539]
11. Dickinson M, **Basu A**. Multilevel modeling and practice-based research. *Annals of Family Medicine* 2005; 3(Supp 1): S52-S60.

12. Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. *Journal of Health Economics* 2005; 24(4): 751-773. [PMID: 15960995]
13. Basu A Extended generalized linear models: Simultaneous estimation of link and variance functions. *The Stata Journal* 2005; 5(4): 501-516.
14. Lindau ST, Basu A, Leitsch SA. Health literacy as a predictor of follow-up after an abnormal pap smear: A prospective study. *Journal of General Internal Medicine* 2006; 21(8): 829 – 834. [PMID: 16881942]
15. Basu A, Meltzer HY, Dukic V. Estimating transitions between symptom severity states over time in schizophrenia: A Bayesian meta-analytic approach. *Statistics in Medicine* 2006; 25(17): 2886 - 2910. [PMID: 16220519]
16. Basu A, Arondekar BV, Rathouz P. Scale of interest versus scale of estimation: Comparing alternative estimators for the incremental costs of a comorbidity. *Health Economics* 2006; 15(10): 1091-1107. [PMID: 16518793]
17. Basu A, Meltzer HY. Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. *Schizophrenia Research* 2006; 86(1-3): 99-109. [PMID: 16753284]
18. Basu A, Manning WG. A test for proportional hazards assumption within the class of exponential conditional mean framework. *Health Services and Outcomes Research Methodology* 2006; 6(3-4): 81-100.
19. Basu A, Meltzer D. Value of information on preference heterogeneity and individualized care. *Medical Decision Making* 2007; 27(2):112-127. [PMID: 17409362]
20. Huang ES, Basu A, Finch M, Frytak J, Manning WG. The complexity of medication regimens and test ordering for patients with diabetes from 1995 to 2003. *Current Medical Research and Opinion* 2007; 23(6): 1423-1430. [PMID: 17559738]
21. Basu A, Heckman J, Navarro-Lozano S, Urzua S. Use of instrumental variables in the presence of heterogeneity and self-selection: An application to treatments of breast cancer patients. York Health Econometrics and Data Group (HEDG) Working Paper 07/07. (with Editorial) *Health Economics* 2007; 16(11): 1133 -1157. [PMID: 17910109]
22. Yin W, Basu A, Zhang J, Rabbani A, Meltzer DO, Alexander GC. The impact of the Medicare Part D prescription drug benefit on drug utilization and out-of-pocket expenditures. (with Editorial) *Annals of Internal Medicine* 2008; 148: 169-177. [PMID: 18180465]
23. Dale W, Basu A, Meltzer D, Elstein A. Predicting utility ratings for joint health states from single health states in prostate cancer: Empirical testing of alternative theories. *Medical Decision Making* 2008; 28(1): 102 – 112. [PMID: 18057188]
24. Alexander GC, Zhang J, Basu A. Characteristics of patients receiving pharmaceutical samples and association between sample receipt and out-of-pocket prescription costs. *Medical Care* 2008; 46: 394-402.[ PMID: 18362819]
25. Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modeling. *Journal of Health Economics* 2008; 27(3):531-543. [PMID: 18192044]
26. Basu A, Paltiel DA, Pollack HA. Social costs of robbery and the cost-effectiveness of substance abuse treatment. *Health Economics* 2008; 17(8): 926-948. [PMID: 17992708]
27. Van Voorhees BW, Paunesku D, Kuwabara SA, Basu A, Gollan J, Hankin BL, Melkonian S, Reinecke M. Protective and vulnerability factors predicting new-onset depressive episode in a representative of US adolescents *Journal of Adolescent Health* 2008;42(6):605-16.[ PMID: 18486870]
28. Van Voorhees BW, Ellis JM, Gollan J, Basu A. Predicting future risk of depressive episode in adolescents: the Chicago Adolescent Depression Risk Assessment (CADRA). *Annals of Family Medicine* 2008 Nov-Dec;6(6):503-511 [PMID: 19001302]
29. Basu A, Dale W, Elstein A, Meltzer D. A Linear Index for Predicting Joint Health States Utilities from Single Health States Utilities. *Health Economics* 2009; 18(4): 403-419. [PMID: 18773392]
30. Basu A, Manning WG. Issues for the next generation of healthcare costs analyses. *Medical Care* 2009; 47(7\_Supplement\_1):S109-S114. [PMID: 19536022]
31. Meltzer D, Basu A, Meltzer HY. Comparative effectiveness research for antipsychotic medications: How much research is enough? *Health Affairs* 2009; 28(5): w794-w808 [PMID: 19622539]
32. Huang E, Basu A, O'Grady M, Capretta JC. Using clinical information to project federal health care spending. *Health Affairs* 2009; 28(5):w978-w990 [PMID: 19723699]
33. Huang E, Basu A, O'Grady M, Capretta J. Projecting the future diabetes population size and related costs for the United States. *Diabetes Care* 2009; 32:2225-2229. [PMID: 19940225]
34. Basu A. Individualization at the heart of comparative effectiveness research: The time for *i*-CER has come. *Medical*

- Decision Making* 2009; 29(6): N9-N11. [PMID: 19959807] [<http://mdm.sagepub.com/cgi/reprint/29/6/NP9>]
35. **Basu A**, Yin W, Alexander CG. Impact of Medicare Part D on the prescription utilization of elderly dual-eligible patients. *2008 NBER Working Paper* No. w14413. *Health Services Research* 2009; 45(1): 133-151. [PMID: 20002765]
  36. Shah LM, King AC, **Basu A**, Krishnan JA, Borden WB, Meltzer D, Arora V. Effect of clinician advice and patient preparedness to quit on subsequent quit attempts in hospitalized smokers. *Journal of Hospital Medicine* 2010; 5(1): 26-32. [PMID: 20063403]
  37. **Basu A**. Forecasting distribution of body-mass index categories in United States: Is there more room for growth? *Medical Decision Making* 2010; 30(3): E1-E11.
  38. **Basu A**, Dale William, Elstein A, Meltzer D. A time trade-off method for eliciting partner's quality of life due to patient's health states in prostate cancer. *Medical Decision Making* 2010; 30(3): 355-365.
  39. Huang E, O'Grady M, **Basu A**, Winn A, John P, Lee J, Meltzer D, Kollman C, Laffel L, Tamborlane W, Weinzimer S, Wysocki T. The cost-effectiveness of continuous glucose monitoring in Type 1 diabetes. *Diabetes Care* 2010; 33(6): 1269-1274.
  40. **Basu A**, Manning WG. Estimating life-time or episode cost of illness under censoring. York Health Econometrics and Data Group (HEDG) Working Paper 09/09. *Health Economics* 2010; 19(9): 1010-1028.
  41. Meltzer D, **Basu A**, Conti R. The Economics of comparative effectiveness studies: Societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness research. *PharmacoEconomics* 2010; 28(10):843-853
  42. Arora V, Fish M, **Basu A**, Olson J, Plein C, Suresh K, Sachs G, Meltzer DO. Relationship Between Quality of Care for Hospitalized Vulnerable Elders and Post-Discharge Mortality. *Journal of the American Geriatrics Society* 2010; 58(9): 1642-8.
  43. **Basu A**, Meltzer D. Quantitative methods for valuing comparative effectiveness information. *Biopharmaceutical Report* Fall 2010; 17(2): 2-10.
  44. Dale W, Bilir SP, Hemmerich J, **Basu A**, Elstein A, Meltzer D. The prevalence, correlates, and impact of logically inconsistent preferences in utility assessments for joint health states in prostate cancer. *Medical Care* 2011; 49(1): 59-66.
  45. **Basu A**. Economics of individualization in comparative effectiveness research and a basis for a patient-centered healthcare. 2011 *NBER Working Paper* No. w16900. *Journal of Health Economics* 2011; 30(3): 549-559.
  46. **Basu A**, Polsky D, Manning WG. Estimating treatment effects on healthcare costs under exogeneity: Is there a 'magic bullet'? York Health Econometrics and Data Group (HEDG) Working Paper 08/11; *2008 NBER Working Paper* No. w14086. *Health Services and Outcomes Research Methodology* 2011; 11:1-26.
  47. **Basu A**, Jena A, Philipson T. Impact of comparative effectiveness research on health and healthcare spending. 2010 *NBER Working Paper* No. w15633. *Journal of Health Economics* 2011; 30(4): 695-706.
  48. Lee J, Rhee K, O'Grady MJ, **Basu A**, Winn A, John P, Meltzer DO, Koleman C, Laffel L, Lawrence J, Tamborlane WV, Wysocki T, Xing D, Huang ES. Health utilities for children and adults with type 1 diabetes. *Medical Care* 2011; 49(10): 924-931.
  49. **Basu A**. Estimating decision-relevant comparative effects using instrumental variables. *Statistics in Biosciences* (Special Issue on Comparative Effectiveness Research) 2011; 3(1): 6-27.
  50. Helfand M, Tunis S, Whitlock EP, Pauker SG, **Basu A**, Chilingerian J, Harrell FE, Meltzer DO, Montori VM, Shepard DS, Kent DM and the Methods Work Group of the National CTSA Strategic Goal Committee on Comparative Effectiveness Research. A CTSA agenda to advance methods for comparative effectiveness research. *Clinical and Translational Science* 2011; 4(3): 188-198.
  51. Meltzer D, Hoomans T, Chung JW, **Basu A**. Minimal Modeling Approaches to Value of Information Analysis for Health Research. *Medical Decision Making* 2011; 31(6): E1-E22.
  52. **Basu A**, Kee RA, Buchanan D, Sadowski LS. Comparative cost analysis of housing and case management program for chronically ill homeless adults compared to usual care. *Health Services Research* 2012; 47(1pt2): 523-543.
  53. **Basu A**, Manca A. Regression estimators for generic health-related quality of life and quality-adjusted life-years. *Medical Decision Making* In Press.
  54. **Basu A**, Meltzer D. Private manufacturers' thresholds to invest in comparative effectiveness trials. *PharmacoEconomics* In Press.
  55. **Basu A**, Meltzer HY. Tying Comparative Effectiveness Information to Decision Making and the Future of CER Designs: The

case for Antipsychotic Drugs. *Journal of Comparative Effectiveness Research* In press.

#### PUBLICATIONS (under review)

56. Evans HL, **Basu A**. Exploring comparative effect heterogeneity with instrumental variables: prehospital intubation and mortality.
57. **Basu A**, Jena AB, Goldman DP, Philipson TJ, Dubois R. Incorporating patient heterogeneity into comparative effectiveness research: Evidence from schizophrenia.
58. Goldberger JJ, **Basu A**, Buxton AE, Cain M, Chen P-S, Constantini O, Exner DV, Lloyd-Jones D, Kadish AH, Lee B, Moss A, Meyerberg R, Olgin J, Passman R, Rosenbaum D, Stevenson W, Tomaselli G, Zareba W, Zipes DP, Zoloth L. Risk Stratification for Sudden Cardiac Death: A Plan for the Future.
59. Meltzer DO, Chung JW, **Basu A**. Effects of hospitalists on 1-year post-discharge resource utilization by Medicare beneficiaries.
60. Hoomans T, Siedenfeld J, **Basu A**, Meltzer DO. Systematizing the Use of Value of Information Analysis in Prioritizing Systematic Reviews

#### IN PREPARATION

61. **Basu A**. Can we make smart choices between OLS versus Contaminated IV estimators?
62. **Basu A**. Person-Centered Treatment (PeT) effects using instrumental variables.
63. Borah BJ, **Basu A**. Covariate effects along the distribution of medication adherence: Comparing conditional versus unconditional quantile regression approaches.
64. **Basu A**, Dukic V. Bayesian hierarchical meta-analysis of treatment effects using pre-post summary data with truncated support: An application with antipsychotic drug trials in schizophrenia.
65. Meltzer D, **Basu A**. Can we better inform medical research spending decisions? An application of value of research techniques to muscular dystrophy.
66. **Basu A**. Flexible models for fractional response variables and outcomes with truncated supports.
67. Meltzer D, Alexander C, **Basu A**. Assessing the empiric cost-effectiveness of new technologies.
68. Meltzer D, **Basu A**, Egleston B, Zhang H. Effects of quality of life on the cost effectiveness analysis of prostate cancer.

#### POSTER PRESENTATIONS

1. **Basu A**, Alexander KS, Dollimore D, Pendse A "Interpretation of hindered settling behavior of concentrated aqueous suspensions of never-dried magnesium hydroxide." *Association of the American Pharmaceutical Scientists*, Midwest Regional Meeting, Chicago, May 1996 and *Pharmaceutics Graduate Students Research Meeting*, Minneapolis, July 1996.
2. **Basu A**, Alexander KS, Dollimore D "Predicting hindered settling behavior in concentrated suspensions." *Association of the American Pharmaceutical Scientists*, Midwest Regional Meeting, Chicago, May 1997.
3. Jani AB, **Basu A**, Heimann R, and Hellman S. "A Number-Needed to Treat analysis for sentinel node dissection for Early-Stage Breast Cancer." *American Radium Society Annual Meeting*, Coronado, CA, April 2001.
4. Akhras K, Arondekar BV, **Basu A**, Walton S "Impact of post-MI heart failure on cost of care and resource utilization." *Heart Failure Society of America*, September 2003.
5. **Basu A**, Meltzer HY, Dukic V "Estimating transitions between symptom severity states for schizophrenic patients." *Twelfth NIMH Biennial Research Conference on the Economics of Mental Health*, September 2004.
6. Elbert H, **Basu A**, Manning W "Trends in the Complexity of Medication Regimens and Test Ordering for Patients with Diabetes from 1996 to 2000" *Society of General Internal Medicine Annual Meeting*, May 2005.

7. Schumann JH, Silverman JB, **Basu A**, Masi C "Per pupil investment in primary and secondary education influences obesity in young adults" *Society of General Internal Medicine Annual Meeting*, April 2006.
8. Schumann JH, Silverman JB, **Basu A**, Masi C "Per pupil education spending effect on teen pregnancy and death rates" *Society of General Internal Medicine Annual Meeting*, April 2006.
9. Meltzer D, **Basu A**, Cuffel B, Loebel A, Alvir J. "Remission in schizophrenia: A comparison of the cost-effectiveness of 2 dose regimens of ziprasidone versus haloperidol treatment in a 3-year double-blind extension study". *International Congress on Schizophrenia Research*, March, 2007.
10. Alexander GC, Zhang JX, **Basu A**. "Characteristics of patients receiving pharmaceutical samples and association between sample use and out-of-pocket prescription costs". *International Society for Pharmacoeconomics and Outcomes Research Annual Meeting*, May 2007.
11. **Basu A**, Meltzer D, Meltzer HY. "Expected value of research on the comparative cost-effectiveness of antipsychotic drugs" *59<sup>th</sup> Institute on Psychiatric Services, October 2007; Society for Medical Decision Making, Annual Meeting, October 2007; American College of Neuropsychopharmacology Annual Meeting, December 2007.*
12. **Basu A**, Manca A. "Regression estimators for quality of life and quality-adjusted life-years" *Society for Medical Decision Making, Annual Meeting, October 2008.*
13. **Basu A**, Yin W, Alexander CG. Impact of Medicare Part D on the prescription utilization of elderly dual-eligible patients. *International Society for Pharmacoeconomics and Outcomes Research, Annual Meeting, May 2009.*